Amneal Pharmaceuticals Inc Stock Price, News & Analysis

Amneal Pharmaceuticals (AMRX) reported Q2 2022 net revenue of $559 million, up 5% from Q2 2021. However, the company faced a net loss of $121 million, primarily due to a $263 million charge for antitrust litigation. Adjusted EBITDA was $135 million, a decrease of 6%. Diluted loss per share stood at $(0.80), while adjusted diluted EPS was $0.19. The company revised its 2022 guidance, projecting net revenue of $2.15 billion to $2.25 billion and adjusted EBITDA of $500 million to $520 million.

Amneal Pharmaceuticals (NYSE: AMRX) appointed Deborah M. Autor as a new independent director on July 29, 2022. Autor brings extensive expertise in the biopharmaceutical industry, particularly in quality, regulatory affairs, and policy. Her background includes key roles at AstraZeneca and Mylan N.V., as well as significant experience with the FDA, where she served as Deputy Commissioner. The addition of Autor aims to strengthen Amneal's leadership as the company targets growth in complex pharmaceutical markets.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will release its second quarter 2022 financial results on August 5, 2022, before market open. A conference call and live webcast will occur at 8:30 a.m. Eastern Time the same day, accessible via the Investor Relations section of Amneal's website. Interested parties can join the call by dialing 1 (844) 200-6205 (U.S.) or 1 (929) 526-1599 (international), using access code 236256. A replay will be available after the call. Amneal is a fully integrated essential medicines company, producing over 250 products.

Amneal Pharmaceuticals (NYSE: AMRX) has launched LYVISPAH, a new baclofen oral granule product approved by the FDA for spasticity associated with multiple sclerosis and spinal cord disorders. Available in 5mg, 10mg, and 20mg packets, LYVISPAH offers flexible dosing options, addressing difficulties some patients face when swallowing pills. This marks Amneal’s first specialty product launch since 2015 and aligns with its strategy to expand its specialty business. The U.S. market for baclofen generated $130 million in annual sales for the year ending March 2022.

Amneal Pharmaceuticals (NYSE: AMRX) recently announced FDA approval for FYLNETRA (pegfilgrastim-pbbk), a biosimilar to Neulasta®, marking its third biosimilar approval in 2022. Developed in partnership with Kashiv Biosciences, FYLNETRA is intended to treat neutropenia in chemotherapy patients. This approval further solidifies Amneal's position in the $28 billion U.S. biosimilars market, where annual pegfilgrastim sales reached $3.1 billion. The company plans to launch FYLNETRA along with its other biosimilars later this year.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced participation in the 2022 Jefferies Healthcare Conference on June 8, 2022, in New York City. Co-CEO Chirag Patel and CFO Tasos Konidaris will represent the company, with Patel hosting a presentation at 8:00 AM ET. A live webcast of the presentation will be available on the Investor Relations section of their website, followed by a replay accessible for 90 days. Amneal specializes in generic and specialty pharmaceuticals, focusing on essential medicines and a diverse product portfolio.

Amneal Pharmaceuticals (NYSE: AMRX) will participate in several investor conferences, including the RBC Healthcare Conference on May 17, 2022, and the UBS Healthcare Conference on May 25, 2022, both in New York City. Additionally, the company will feature in the Barclays CEO Call Series on May 27, 2022, at 10:00 AM Eastern Time. As a fully-integrated essential medicines company, Amneal specializes in generic and specialty pharmaceuticals with a diverse portfolio of over 250 products. For more information, visit www.amneal.com.

Amneal Pharmaceuticals (AMRX) reported Q1 2022 net revenue of $498 million, a 1% increase from Q1 2021. The company faced a net loss of $2 million compared to a net income of $7 million last year. Adjusted EBITDA was $100 million, down 13% year-over-year, and adjusted diluted EPS was $0.12, down from $0.17. Despite challenges, Amneal maintains its 2022 financial outlook with net revenue guidance of $2.15 billion - $2.25 billion and adjusted EBITDA of $540 million - $560 million.